Srinjoy Chakraborti, PhD
About Srinjoy Chakraborti, PhD
Srinjoy Chakraborti, PhD, serves as Principal Scientist in TCR Engineering at Alloy Therapeutics, Inc. He specializes in developing novel therapeutics for various diseases and has extensive experience in protein characterization and engineering.
Current Role at Alloy Therapeutics
Srinjoy Chakraborti serves as Principal Scientist in TCR Engineering at Alloy Therapeutics, Inc. since 2022. In this role, he focuses on the development of novel therapeutics aimed at treating infectious diseases, cancer, autoimmune, and neurological disorders. His work involves utilizing rational design methodologies to create effective treatment options.
Previous Experience in Antibody Engineering
Prior to his current position, Srinjoy worked as a Scientist in Antibody Engineering at Scholar Rock from 2020 to 2022. His responsibilities included applying his expertise in protein characterization and engineering to advance therapeutic solutions in the field of antibody development.
Education and Expertise in Biological Sciences
Srinjoy Chakraborti obtained his Doctor of Philosophy (PhD) in Biological and Biomedical Sciences from the University of Massachusetts Medical School, where he studied from 2010 to 2017. He also holds a Master of Science (M.Sc.) in Medical Microbiology from Kasturba Medical College, completed from 2005 to 2008, and a Bachelor's Degree in Microbiology from Bharati Vidyapeeth, achieved from 2002 to 2005.
Research Fellowship Experience
Srinjoy has significant postdoctoral experience, having worked as a Postdoctoral Research Fellow at Albert Einstein College of Medicine from 2017 to 2018. He furthered his research as a Damon Runyon Sohn Pediatric Cancer Research Fellow at the same institution from 2018 to 2020, contributing to pediatric cancer research initiatives.
Technical Skills and Methodologies
Srinjoy possesses advanced skills in protein characterization assays, including Size Exclusion Chromatography, Bio-Layer Interferometry (BLI), and Surface Plasmon Resonance (SPR). He is experienced in using display platforms such as phage display for protein engineering and has expertise in designing immunological assays to investigate the functional basis of therapeutics.